Expert Insights

Ehab Atallah, MD, provides an update on the management of patients with CML, highlighting new available agents and the role of monitoring for MRD.

Axel Bex, MD, reviews results from the phase 3 IMmotion010 trial showing no benefit to clinical outcomes with adjuvant atezolizumab vs placebo following nephrectomy for patients with renal cell carcinoma and an increased risk of recurrence.

Fred Saad, MD, discusses findings from a biomarker analysis of the phase 3 PROpel trial investigating abiraterone plus olaparib vs abiraterone plus placebo for patients with metastatic castration-resistant prostate cancer.

Paolo Ascierto, MD, reviews 4-year data and a preliminary biomarker analysis from a phase 2 trial exploring the ideal sequential strategy of targeted therapy and immunotherapy for patients with untreated, metastatic BRAFV60-mutated melanoma.

Sungjune Kim, MD, PhD, shares insights from a randomized phase 2 trial exploring first-line combination therapy with nivolumab and ipilimumab for patients with advanced Merkel cell carcinoma, first presented at the 2022 ESMO Congress.

BJ Rimel, MD, shares important tips and insights regarding the care for transgender and special population patients being treated for cancer, a topic she presented at the 2022 GDU Women’s Oncology virtual meeting.

Anne Katz, PhD, RN, shares her insights on talking to patients about the sexual side effects they experience during and after undergoing cancer treatments.

Mitesh Borad, MD, reviews results from a pivotal phase 2 trial investigating derazantinib in chemotherapy-exposed patients with intrahepatic cholangiocarcinoma and FGFR2 fusions, mutations, or amplifications.

Benjamin Miron, MD, discusses a study comparing survival on single-agent immune checkpoint inhibitors in the second-line treatment setting, following either cisplatin or carboplatin, in patients with urothelial carcinoma.

Rajwanth Veluswamy, MD, provides an overview of his presentation at Great Debates and Updates in Lung Cancer covering front-line and second-line treatment options for patients with NSCLC and NTRK fusions.